Fig. 2From: Clinical efficacy and prognosis analysis of treatment regimens for EGFR mutant non-small cell lung cancer and brain metastasis: a retrospective studyPFS, iPFS, ePFS and OS comparison inEGFRm + NSCLC patients with BMs under different regimens. BMs, brain metastases; EGFRm+, EGFR-mutant positive; m, month; PFS: progression-free survival; OS, overall survival; iPFS, intracranial progression-free survival; ePFS, extracranial progression-free survivalBack to article page